Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. Antidote was launched as TrialReach in 2010 and rebranded to Antidote in 2016. We're based in New York, NY and London, U.K. For more information, visit http://www.antidote.me.
Location: United States, Florida
Employees: 11-50
Total raised: $45M
Founded date: 2010
Investors 5
| Date | Name | Website |
| 04.09.2021 | LBO France | lbofrance.... |
| - | BioHealth ... | biohealthi... |
| - | Octopus Ve... | octopusven... |
| - | Amadeus Ca... | amadeuscap... |
| - | Smedvig Ca... | smedvigcap... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.06.2021 | - | $23M | LBO France |
| 12.05.2021 | - | $11M | - |
| 07.09.2017 | - | $11M | - |
Mentions in press and media 22
| Date | Title | Description |
| 07.02.2023 | Antidote and XpertPatient.com partner to empower those new to a cancer diagnosis to easily find clinical trials | Antidote and XpertPatient logos “By joining forces, we are providing those new to cancer with a more holistic view of their options, building confidence and enabling them to be true partners to their doctors during treatment planning.” - Ri... |
| 08.11.2022 | Clinical trial recruitment platform Antidote partners with OneStudyTeam | The two companies will combine technologies to streamline Antidote's patient management experience Antidote is a free clinical trial search engine, serving two sides of the clinical trial marketplace: both patients and the projects looking ... |
| 02.11.2022 | Antidote Technologies and Beyond Celiac to Match Celiac Patients with Research Opportunities | Beyond Celiac and Antidote are collaborating to drive celiac disease research forward. “Partnering with Antidote will help the celiac patient community find and connect to clinical trials in an easy and patient-friendly way.” - Maria Luci, ... |
| 07.07.2022 | Antidote Honored to Receive Silver Award From Global Sustainability Authority EcoVadis | “Our company has been focusing heavily on increasing sustainability and corporate responsibility, and it is gratifying to see our work recognized in such a meaningful way.” - Laurent Schockmel, CEO of Antidote NEW YORK (PRWEB) July 07, 2022... |
| 19.04.2022 | Unlearn.AI, a startup developing a ‘digital twin’ service for clinical trials, raises $50M | The idea of digital twins — digital representations of humans built with computer models — for medical research is gaining traction in both the private and academic sectors. With predictive simulation technology, some experts say that digit... |
| 05.01.2022 | Antidote Technologies Promotes Dave Mauro to Chief Revenue Officer | Dave Mauro, CRO, Antidote Technologies “During his time at Antidote, Dave’s contributions have been instrumental in driving the growth of the business and helping to build a great culture for our employees,” said Laurent Schockmel, CEO, Ant... |
| 02.08.2021 | Antidote Technologies’ Business Development Leader Dave Mauro Named to the 2021 PharmaVOICE 100 | Dave Mauro, EVP of Business Development at Antidote “Beyond [Dave's] business development acumen, he is a constant source of positive energy on our team and PharmaVOICE’s recognition only highlights the fantastic leader that he is.” - Laure... |
| 30.06.2021 | Today's entrepreneur: Laurent Schockmel, CEO of Antidote | The only way you can win and grow is to be relentless with the execution of your strategy Today's entrepreneur is Laurent Schockmel, CEO of Antidote, a free clinical trial search engine, which serves both sides of the clinical trial marketp... |
| 04.06.2021 | LBO France’s Digital Health team leads a $23 million growth round in Antidote | Press Release |
| 03.06.2021 | Antidote Technologies Raises $23M in Funding | Antidote Technologies, a US and UK based digital health company, raised $23M in funding. The round was led by LBO France, which is investing $10m through its Digital Health 2 fund, with participation from existing investors Merck Global Hea... |
Show more